Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick S Parfrey

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
BMJ Open|February 12, 2013
Dietary patterns and colorectal cancer recurrence and survival: a cohort studyYun Zhu, Hao Wu, Peizhong Peter Wang, et al.
The British Journal of Nutrition|October 29, 2013
Dietary N-nitroso compounds and risk of colorectal cancer: a case-control study in Newfoundland and Labrador and Ontario, CanadaYun Zhu, Peizhon Peter Wang, Jing Zhao, et al.
Journal of the National Cancer Institute|March 22, 2007
MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancerStavroula Raptis, Miralem Mrkonjic, Roger C Green, et al.
Circulation|November 23, 2011
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experienceHicham Skali, Hans-Henrik Parving, Patrick S Parfrey, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 24, 2010
Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based studyTyler A Wish, Angela J Hyde, Patrick S Parfrey, et al.
Carcinogenesis|February 10, 2011
Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patientsJames B Rawson, Michael Manno, Miralem Mrkonjic, et al.
Journal of the American Society of Nephrology : JASN|December 16, 2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE TrialSharon M Moe, Safa Abdalla, Glenn M Chertow, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 25, 2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialPatrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, et al.
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
BMJ Open|February 12, 2013
Dietary patterns and colorectal cancer recurrence and survival: a cohort studyYun Zhu, Hao Wu, Peizhong Peter Wang, et al.
The British Journal of Nutrition|October 29, 2013
Dietary N-nitroso compounds and risk of colorectal cancer: a case-control study in Newfoundland and Labrador and Ontario, CanadaYun Zhu, Peizhon Peter Wang, Jing Zhao, et al.
Journal of the National Cancer Institute|March 22, 2007
MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancerStavroula Raptis, Miralem Mrkonjic, Roger C Green, et al.
Circulation|November 23, 2011
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experienceHicham Skali, Hans-Henrik Parving, Patrick S Parfrey, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 24, 2010
Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based studyTyler A Wish, Angela J Hyde, Patrick S Parfrey, et al.
Carcinogenesis|February 10, 2011
Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patientsJames B Rawson, Michael Manno, Miralem Mrkonjic, et al.
Journal of the American Society of Nephrology : JASN|December 16, 2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE TrialSharon M Moe, Safa Abdalla, Glenn M Chertow, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 25, 2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialPatrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, et al.
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
Pageof 16